The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

The therapy is a highly advanced form of radiation therapy that uses charged particles in the form of a proton that that gets ...

On the 6th, the Department of Urology at the Catholic University of Korea's Seoul St. Mary's Hospital (Professor Lee Ji-yeol) ...

St. Charles, revealed that he was diagnosed with prostate cancer, had surgery and because of early detection, it did not ...

Prostate cancer is the most common cancer in men, with about 1-in-8 expected to be diagnosed in their lifetime.

Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department of Radiation ...